ADMA
ADMA Biologics Inc
9.80$
+3.2%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 88.5% | 89.8% | 91.4% | 58.5% | 50.1% | 67.5% | 74.0% | 75.6% | 77.6% | 78.1% | 67.8% | 74.7% | |
| 63.2% | 44.0% | 41.9% | 39.9% | 25.6% | 21.0% | 26.9% | 18.5% | 24.8% | 15.6% | 21.1% | 14.0% | |
| 80.3% | 70.9% | 64.6% | 39.9% | 25.6% | 21.0% | 26.9% | 18.5% | 24.8% | 15.6% | 21.1% | 14.0% | |
| 1.4% | 3.9% | 4.3% | 3.6% | 1.6% | 2.7% | 6.4% | 10.3% | 4.4% | 8.3% | 10.2% | 25.4% | |
| 6.3% | 14.5% | 21.2% | 11.7% | 20.9% | 41.8% | 39.3% | 45.1% | 46.9% | 52.5% | 34.8% | 33.1% | |
| 10.4% | 10.1% | 8.4% | 28.2% | 33.9% | 25.0% | 22,079.0% | 18.4% | 16.7% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 3.3% | 4.0% | 2.8% | 1.7% | 1.3% | 1.0% | 1.1% | 0.7% | 0.6% | |
| 0.0% | 0.0% | 0.0% | 4.5% | 4.5% | 2.5% | 1.2% | 0.6% | 0.3% | 0.2% | 0.1% | 0.1% | |
| 77.9% | 96.5% | 118.8% | 62.7% | 77.8% | 79.4% | 57.5% | 48.9% | 56.4% | 58.9% | 28.6% | 23.5% | |
| 15.4% | 17.8% | 47.4% | 8.7% | 10.8% | 11.0% | 9.6% | 11.0% | 11.3% | 15.1% | 11.4% | 11.1% | |
| 0.1% | 0.1% | 25.9% | 3.1% | 0.0% | 0.2% | 0.2% | 0.2% | 0.3% | 0.3% | 0.2% | 0.6% | |
| 6.5% | 8.8% | 10.8% | 5.5% | 6.6% | 7.2% | 5.3% | 4.5% | 3.8% | 4.8% | 4.1% | 3.6% | |
| 54.3% | 60.1% | 52.0% | 26.0% | 32.9% | 53.7% | 44.8% | 34.3% | 41.0% | 39.7% | 14.8% | 11.1% | |
| 22.1% | 3.5% | -18.8% | 37.3% | 22.2% | 20.6% | 42.5% | 51.1% | 43.6% | 41.1% | 71.4% | 76.5% | |
| -255.1% | -368.6% | -451.5% | -139.5% | -243.5% | -208.3% | -163.9% | -149.2% | -137.2% | -153.8% | -63.1% | -25.9% | |
| 34.1% | 43.9% | 51.3% | 21.2% | 50.8% | 42.8% | 41.5% | 50.5% | 56.8% | 68.0% | 49.8% | 39.2% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.